Home » Stocks » BLCM

Bellicum Pharmaceuticals, Inc. (BLCM)

Stock Price: $3.14 USD 0.20 (6.80%)
Updated May 14, 2021 4:00 PM EDT - Market closed
After-hours: $2.96 -0.18 (-5.73%) May 14, 7:42 PM
Market Cap 26.12M
Revenue (ttm) 500,000
Net Income (ttm) -7.72M
Shares Out 5.76M
EPS (ttm) -1.34
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 14
Last Price $3.14
Previous Close $2.94
Change ($) 0.20
Change (%) 6.80%
Day's Open 2.95
Day's Range 2.94 - 3.26
Day's Volume 156,067
52-Week Range 2.62 - 9.56

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Enrolled first patient in Phase 1/2 clinical trial for BPX-603 in solid tumors that express HER2

1 month ago - GlobeNewsWire

Management to host webcast and conference call on Tuesday, March 30, 2021 at 5 p.m. ET / 2 p.m. PT Management to host webcast and conference call on Tuesday, March 30, 2021 at 5 p.m. ET / 2 p.m. PT

1 month ago - GlobeNewsWire

HOUSTON, March 04, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the publication...

2 months ago - GlobeNewsWire

HOUSTON, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that the U.S. Fo...

3 months ago - GlobeNewsWire

Want to try some out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Other stocks mentioned: BJ, LMNL, QFIN, VCNX, VIVO
4 months ago - Zacks Investment Research

Bellicum Pharmaceuticals (BLCM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

4 months ago - Zacks Investment Research

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

Other stocks mentioned: AUDC, INUV, ORTX
4 months ago - Zacks Investment Research

HOUSTON, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced enrollment and a...

5 months ago - GlobeNewsWire

HOUSTON, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that it has been...

5 months ago - GlobeNewsWire

Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities ...

5 months ago - Insider Monkey

Bellicum Pharmaceuticals (BLCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

5 months ago - Zacks Investment Research

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Other stocks mentioned: CAH, FNF, GLUU, QLYS
5 months ago - Zacks Investment Research

Strategic focus on clinical GoCAR-T ® programs with plans to initiate Phase 1/2 enrollment of BPX-601 in mCRPC and BPX-603 in HER2+ solid tumors by end of year

6 months ago - GlobeNewsWire

HOUSTON, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the closing of i...

6 months ago - GlobeNewsWire

Shares of Bellicum Pharmaceuticals Inc. plunged 35.1% in midday trading Friday, putting them on track for their biggest-ever one-day drop, after the clinical stage biopharmaceutical company said it was ...

6 months ago - Market Watch

HOUSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the pricing of a...

6 months ago - GlobeNewsWire

HOUSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced interim data fro...

6 months ago - GlobeNewsWire

HOUSTON, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity induceme...

7 months ago - GlobeNewsWire

HOUSTON, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that management...

7 months ago - GlobeNewsWire

Bellicum Pharmaceuticals' stock continues to be pounded into submission by the market. Now that the market has obliterated any premium left in the stock, I am looking to accumulate.

8 months ago - Seeking Alpha

HOUSTON, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that manageme...

8 months ago - GlobeNewsWire

Bellicum Pharmaceuticals, Inc. (BLCM) CEO Richard Fair on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

Management to host webcast and conference call on Thursday, August 6, 2020 at 5 p.m. ET / 2 p.m. PT Management to host webcast and conference call on Thursday, August 6, 2020 at 5 p.m. ET / 2 p.m. PT

9 months ago - GlobeNewsWire

HOUSTON, June 15, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced clearance by t...

11 months ago - GlobeNewsWire

Top Ranked Momentum Stocks to Buy for June 1st

Other stocks mentioned: AGFS, BAND, FLWS
11 months ago - Zacks Investment Research

HOUSTON, May 27, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the publication...

11 months ago - GlobeNewsWire

Bellicum Pharmaceuticals (BLCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

11 months ago - Zacks Investment Research

HOUSTON, April 30, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity induce...

1 year ago - GlobeNewsWire

Purchase price of $15 million from sale of manufacturing, office and laboratory facility

1 year ago - GlobeNewsWire

Bellicum Pharmaceuticals, Inc. (BLCM) CEO Richard Fair on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Bellicum Pharmaceuticals (BLCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

HOUSTON, Feb. 28, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducem...

1 year ago - GlobeNewsWire

HOUSTON, Feb. 05, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM) (“Bellicum” or the “Company”), a leader in developing novel, controllable cellular immunotherapies for cancers,...

1 year ago - GlobeNewsWire

HOUSTON, Jan. 31, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood diso...

1 year ago - GlobeNewsWire

HOUSTON, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today presented new Phase 1 tr...

1 year ago - GlobeNewsWire

Houston manufacturing facility and portions of Bellicum’s Technical Operations and Quality staff to be acquired by MD Anderson

1 year ago - GlobeNewsWire

Bellicum’s proprietary technology licensed for use in CD19 CAR NK program Bellicum’s proprietary technology licensed for use in CD19 CAR NK program

1 year ago - GlobeNewsWire

iMC activation enhances innate NK cell cytotoxicity against tumor cell lines in vitro

1 year ago - GlobeNewsWire

Bellicum Pharmaceuticals, Inc. (BLCM) CEO Rick Fair on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Bellicum Pharmaceuticals (BLCM) delivered earnings and revenue surprises of -1.75% and -65.67%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the s...

1 year ago - Zacks Investment Research

Bellicum Pharmaceuticals (BLCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

HOUSTON, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood dis...

1 year ago - GlobeNewsWire

The stock has gained 20% since Baker Bros. disclosed its stake in the company.

1 year ago - Seeking Alpha

Bellicum has produced some solid trial data for its lead therapy candidate BPX-501 in pediatric HSCT patients.

1 year ago - Seeking Alpha

HOUSTON, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood diso...

1 year ago - GlobeNewsWire

Closing of $57.5 Million Public Offering of Preferred Stock and Warrants and Receipt of $12.1 Million Option Fee Related to Private Placement of up to $70.0 Million of Preferred Stock and Warrants  Clos...

1 year ago - GlobeNewsWire

Bellicum Pharmaceuticals (BLCM) delivered earnings and revenue surprises of -7.41% and 497.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Bellicum Pharmaceuticals (BLCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Bellicum recently publicized Rivo-cel hit the primary endpoint of event-free survival rate at 180 days of 90.9% in their BP-004 European registrational study.

1 year ago - Seeking Alpha

Bellicum Pharmaceuticals recently reported promising data for BPX-601 at ASCO. The company's GoCAR-T program is taking aim at solid tumors and could be a leading therapy if approved.

1 year ago - Seeking Alpha

About BLCM

Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trial... [Read more...]

Industry
Biotechnology
IPO Date
Dec 18, 2014
CEO
Richard Fair
Employees
16
Stock Exchange
NASDAQ
Ticker Symbol
BLCM
Full Company Profile

Financial Performance

In 2020, BLCM's revenue was $500,000, a decrease of -93.00% compared to the previous year's $7.14 million. Losses were -$7.72 million, -93.13% less than in 2019.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for BLCM stock is "Buy." The 12-month stock price forecast is 4.50, which is an increase of 43.31% from the latest price.

Price Target
$4.50
(43.31% upside)
Analyst Consensus: Buy